expressed in brain. 8 mouse sCd3 is found in skin, preputial glands, and Harderian glands, 4 whereas mouse sCd4 is predominately expressed in heart. 5 Human sCd1 is closely related to mouse sCd1 with 84% amino acid identity. it is ubiquitously expressed with high levels in brain, adipose tissue, and liver tissue. 6 in contrast, human sCd5 has low amino acid identity with either mouse or human isoforms at only 33% identity with human sCd1. Human sCd5 is found predominately in brain and pancreas. 7, 9 the role of the isoforms in different tissues is not clearly understood. sCd1 in the liver is highly regulated by nutritional status, with increased levels occurring upon feeding. 10 mice deficient in the sCd1 gene globally exhibit reduced body adiposity, increased insulin and leptin sensitivity, resistance to diet-induced obesity, and increased lipid oxidation. [11] [12] [13] Because of the reduction of oleic acid in the skin and tears, both skin and eye abnormalities are observed. 14 However, using antisense oligonucleotides, decreased sCd1 protein levels in the liver will reduce diet-induced obesity and steatosis as well as improve insulin sensitivity without eye or skin abnormalities. 15 more recently, adipose-specific knockdown of sCd1 in mice has shown elevated Glut1 levels suggesting the importance of sCd1 in glucose metabolism. 16 sCd2-deficient neonatal mice show a defective skin permeability barrier, suggesting that sCd2 is important in early skin and liver development in rodents. 17 in humans as well as rodents, elevated sCd activity has been associated with both insulin resistance and hypertriglyceridemia. [18] [19] [20] [21] taken together, these studies suggest that sCd1 plays a role in both lipogenesis and glucose metabolism and could be a potential drug target for human obesity and type 2 diabetes.
to aid in the development of human sCd inhibitors, an enzyme activity assay using rat liver microsomes from sugarfed rodents or semi-purified recombinant human sCd1 was developed based on known literature assays. 22 these assays involve measuring the desaturase activity by determining the conversion of radiolabeled stearoyl-Coa into radiolabeled oleoyl-Coa and resolving by thin-layer chromatography, highperformance liquid chromatography (HPlC), or charcoal trapping of the substrate and counting radio activity. numerous steps are involved, including lipid saponification, washes, and filtering. Cytochrome b5 and cytochrome b5 reductase are also required for sCd1 activity, further complicating the system. overall, the enzyme activity assay is time-consuming and not amenable to volumes less than 50 µl. this limits the assay to a 384-well plate format and a medium throughput. to screen a sample collection of more than 1.6 million compounds, a highthroughput sCd1 assay was required. this article describes the development of a scintillation proximity binding assay (sPa) for human sCd1 and the resultant ultra-high-throughput screening (uHts) campaign using this sPa assay.
MAterIALS And MetHodS
Materials rabbit anti-FlaG m2 antibody and anti-FlaG m2 affinity gel were obtained from sigma (st. louis, mo). n-dodecylmaltoside (ddm) was obtained from anatrace (santa Clara, Ca). desalting spin columns were from Pierce (rockford, il). sPaantimouse beads (polyvinyltolune [PVt], yttrium silicate [ytt], and yttrium oxide [yo] based) were supplied by Perkinelmer (Waltham, ma). radiolabeled stearoyl-Coa was from Ge Healthcare (Piscataway, nJ). all other chemicals were of reagent grade from sigma.
Enzymes
the full-length cdna of human sCd1 containing an n-terminal FlaG construct (dykddddk) separated by a 6-amino acid linker (sGGsGG) was subcloned into pFastBac1 (invitrogen, Carlsbad, Ca) and subsequently transformed into dH10Bac Escherichia coli cells to generate a recombinant bacmid using the Bac-to-Bac Baculovirus expression system (invitrogen). the resultant bacmid was then used to transfect and express sCd1 in Sf9 insect cells using standard techniques. the Sf9 cell pellet was lysed by brief sonication in cold lysis buffer (50 mm tris [pH 7.5] containing 1% protease inhibitor cocktail) and centrifuged at 2500 g to obtain the s2.5 lysate human sCd1 fraction. this fraction was further purified using anti-FlaG m2 affinity purification by diluting s2.5 fraction fourfold with affinity buffer (50 mm tris [pH 7.5], 0.1% ddm, 150 mm sodium chloride) and adding 1 µl of washed anti-FlaG m2 affinity gel per 40 µg of s2.5 lysate. the sample with affinity gel was gently agitated for 2 h and then pelleted at 3300 g for 1 min followed by several washes with affinity buffer to remove unbound proteins. the bound FlaG-sCd1 was eluted by a 2-h incubation of the washed gel in affinity buffer containing 150 µg/ml 3 × FlaG peptide followed by pelleting the gel at 10 000 g for 1 min. Protein concentration was determined by Bradford assay using bovine serum albumin (Bsa) as the standard and protein purity estimated by sodium dodecyl sulfate (sds) gel electrophoresis. the recovered supernatant containing ~80% pure human FlaG-sCd1 and 3 × FlaG peptide was stored at −80 °C. rat liver microsomal sCd1 was prepared as outlined in the patent. 22 Briefly, livers from male sprague dawley rats fed a high-carbohydrate diet for 3 days were obtained and homogenized (1:10 w/v) in a buffer containing 250 mm sucrose, 1 mm edta, 5 mm dithiothreitol (dtt), and 50 mm tris-HCl (pH 7.5). after a 100 000 g centrifugation for 60 min, the liver microsome pellet was suspended in a buffer containing 100 mm sodium phosphate, 20% glycerol, and 2 mm dtt and stored at −80 °C. Protein concentration was determined by Bradford assay using Bsa as the standard.
Radioactive ligand, [ 3 H]AZE
tritiated-labeled aze was prepared as described 23 with approximately 50% tritium incorporation, resulting in a specific activity of 30 Ci/mmol with a concentration of 0.3 mm (9 µCi/ µl) dissolved in a 2:1 acetonitrile/water mixture.
Enzyme activity assays
rat liver microsomal assay using tritiated stearoyl-Coa as substrate is described in the patent. 22 Briefly, in a 96-well plate, 2 µl of compound serially diluted threefold in dmso was added to 200 µl of an enzyme mixture containing 70 µg/ml rat liver microsomes, 0.1 mm coenzyme a, 5 mm adenosine triphosphate (atP), 2 mm nadH, and 0.03% triton X-100 in 0.1 m tris-HCl (pH 7.5). the solution was incubated for 15 min, and then the reaction was initiated by addition of 20 µm stearoyl-Coa containing 20 µCi/ml 3 H-labeled stearoyl-Coa. then, 80 µl of reaction mixture was transferred to a charcoal solution containing 9.5% by weight charcoal in a 4:80 ethanol/water solution. after 30 min of shaking, 25 µl of 2 m calcium chloride was added to the charcoal/reaction mixture, shaken for 5 min, and then spun at 1500 g for 15 min at room temperature. next, 50 µl of supernatant was transferred into a fresh 96-well plate containing 150 µl scintillant, shaken for 30 min, and counted. iC 50 values were obtained from the nonlinear regression fit of an 11-point dose-response curve of the counts using a four-parameter sigmoidal fit in sigmaPlot (systat software, san Jose, Ca).
For the [ 14 C]-stearoyl-Coa HPlC assay, 200 µg/ml of s2.5 Sf9 lysate containing recombinant human sCd1 or sCd5 was premixed for 10 min at room temperature with 2 µg/ml cytochrome b5 and 9 µg/ml cytochrome b5 reductase in buffer containing 0.1 mm tris-HCl (pH 7.4) and 0.005% triton X-100 in a final volume of 40 µl. then, 1 µl of compounds in dmso was added and preincubated for 15 min before initiation of the reaction with addition of 10 µl of 15 µm [ 14 C]-labeled stearoyl-Coa and 1 µl of 100 mm βnadH. after 5 to 30 min, depending on the activity level, the reaction was stopped by addition of koH quenching solution containing 30% 8 n koH and 5 mg/ml stearic acid and 5 mg/ml oleic acid in 70% ethanol. the lipids were saponified by heating at 65 °C for 30 min and acidified by addition of 10 µl formic acid to the cooled solution. lipids were analyzed by HPlC using a zorbax extend C18 reverse-phase column (agilent technologies, santa Clara, Ca). stearic and oleic acids were separated at 2 ml/min over a 95% to 100% gradient of acetonitrile/0.1% formic acid in water/0.1% formic acid. typical retention times were 2.5 min for oleic acid and 3.5 min for stearic acid. Percentage inhibition was calculated from the area of oleic acid over the sum of oleic and stearic acid integration areas. iC 50 values were obtained from the nonlinear regression fit of an 11-point dose-response curve of the counts using a four-parameter sigmoidal fit in sigmaPlot.
Spin column binding
radioactive [ 3 H]aze was diluted to 700 nm in dmso to give 21 nCi/ µl. to a final volume of 50 µl buffer (50 mm tris [pH 7.5] with 0.2% ddm) was added 5 µl of 700 nm [ 3 H]aze with or without 1 µl of 50 µm nonradioactive aze and 1 µl of 0.2 mg/ml serially diluted (twofold) purified human FlaG-sCd1. the mixture was incubated for 10 min, and then 45 µl was filtered using protein desalting columns following the manufacturer's protocol. the flow-through was collected, 5 ml of scintillant was added, and the sample was counted.
96-Well SPA assay
all sPa binding assay development studies were conducted in 50 µl tris-HCl (pH 7.5) buffer containing 0.01% or 0.1% ddm as outlined in the individual results. in general, [ 3 H]aze was incubated with sCd protein from various sources (purified human FlaG-sCd1, s2.5 lysate human FlaG-sCd1, rat microsomal sCd1) with or without 15 µg/ml FlaG antibody. then, 50 µl of sPa antimouse beads (PVt or ytt, 100 µg) was added, and the reaction mixture was shaken for 10 min. Plates were counted on a microbeta 96-well plate counter (Perkinelmer).
For competition binding studies, a final volume of 100 µl buffer (50 mm tris-HCl [pH 7.5], 0.01% ddm) containing 10 nm [ 3 H]aze was mixed with a threefold serial dilution of inhibitors in dmso starting at 15 µm (1.5% dmso final). then, 50 µl of antimouse yttrium silicate sPa beads (100 µg) was added and the mixture shaken for 10 min. Plates were counted on a microbeta 96-well plate counter.
nonspecific binding was defined as the radioactive ligand binding to the sPa beads in the absence of enzyme. data from a saturation curve for specific binding of [ 3 H]aze were fitted to a one-site equilibrium binding equation using nonlinear regression fit from sigmaPlot to obtain k d values. iC 50 values were calculated from nonlinear regression four-parameter fits of dose-response curves using sigmaPlot. the window for an assay was defined as the ratio of the maximum signal obtained at a given ligand and enzyme concentration over the nonspecific binding.
1536-Well HTS assay
the Hts screen was run using the following buffers and volumes. into each 1536 well was added 2 µl of 0.125 mg/ml s2.5 Sf9 lysate of human FlaG-sCd1 diluted in enzyme buffer (50 mm tris-HCl [pH 7.5], 0.01% ddm), 50 nl of 2 mm compound in dmso, 5 µl of 5 mg/ml donkey antirabbit yttrium oxide imaging beads (specific for Viewlux imaging), and 2 µl of 60 nm [ 3 H]aze (1.8 nCi/ µl). the solution was mixed and incubated for 10 min followed by measurement of counts on the Viewlux CCd imaging system (Perkinelmer). nonspecific binding was defined as the radioactive ligand binding to the sPa beads in the absence of enzyme. maximum binding (100%) was defined for each plate as the average of 8 samples containing [ 3 H]aze, enzyme, and dmso without competing compounds less the nonspecific binding.
reSuLtS

Identification of radioligand
the structure of the radioligand [ 3 H]aze is shown in Figure 1 . the potency of unlabeled aze was measured using the rat microsomal sCd1 and human recombinant sCd1 [ 14 C]-stearoyl-Coa HPlC assay. aze was found to have an iC 50 of 2 and 8 nm against rat microsomal sCd1 and human sCd1, respectively. more important, unlike many other known sCd inhibitors of this potency, aze had low binding to both plastic and glass, resulting in a lower nonspecific binding to either plastic or glass scintillation beads and assay plates. 23 
Proof of concept for SPA binding
initial studies were performed to evaluate the binding of [ 3 H]aze to affinity-purified FlaG-tagged human sCd1 using gel filtration. radioactive aze at 70 nm was incubated with varying concentrations of purified human FlaG-sCd1 (1-16 µg/ml) in the presence or absence of competing nonradioactive ligand aze (1 µm). enzyme-bound radioligand was separated from unbound radioligand by passing the mixture through a gel filtration desalting spin column and the amount of bound radioligand measured by counting the resultant flow-through. the radioligand bound to the enzyme in a dose-dependent manner with 40% of [ 3 H]aze binding to 2 µg/ml FlaG-sCd1 and increasing to 75% of [ 3 H]aze binding to 15 µg/ml FlaG-sCd1. the binding of [ 3 H]aze to FlaG-sCd1 was abolished by competition with the nonradioactive ligand aze, indicating that the [ 3 H]aze can bind to purified FlaG-sCd1 in a reversible manner.
SPA bead type and binding mode
an antibody-assembled sPa bead system was evaluated using mouse antiflag antibody and nonpurified human FlaGtagged sCd1 (s2.5 lysate) and two different sPa microbeads: PVt and ytt microspheres coated with antimouse antibody. [ 3 H]aze (12 nm) was incubated for 10 min with varying concentrations of human FlaG-sCd1 s2.5 Sf9 lysate (0-200 µg/ ml) in the presence or absence of anti-FlaG (15 µg/ml) in 50 µl buffer (50 mm tris [pH 7.5], 0.1% ddm). sPa microbeads were added (50 µl) and counts determined. as shown in Figure  2 , human FlaG-sCd1 bound to the ytt beads independent of antibody, whereas the binding to PVt beads was antibody dependent. the signal-to-background ratio was higher with the ytt beads (nine-fold) compared with PVt beads (six-fold). Binding signal was dependent on the presence of human Flag-sCd1 in the lysate as mock-infected Sf9 lysate did not give any counts over background levels (data not shown).
For the enzyme activity assay using purified FlaG-sCd1 or s2.5 Sf9 lysate containing recombinant FlaG-sCd1, the addition of both cytochrome b5 and cytochrome b5 reductase was necessary for desaturase activity. 24 Both cytochrome b5 and cytochrome b5 reductase at various concentrations were added with the purified and lysate preparations of human FlaG-sCd1, and the binding of [ 3 H]aze under the sPa binding conditions was measured. there was no effect of the addition of either cytochrome b5 or cytochrome b5 reductase to sPa assay counts (data not shown).
Incubation time, detergent, SPA bead amount
FlaG-sCd1 was shown to have optimal activity between pH 6.5 and 7.5. 25 For consistency, the same buffer conditions as the rat microsomal activity assay were chosen with tris-HCl buffer at pH 7.5. the association of [ 3 H]aze with FlaG-sCd1 in s2.5 Sf9 lysate or affinity-purified enzyme was rapid and reached nearmaximal levels within 10 min (data not shown). the counts were stable overnight, and plates could be read any time after the initial 10-min incubation. addition of more beads did not enhance the signal, and all studies maintained a 1:1 volume ratio of buffer/ beads. For the sCd1 cell lysate, 0.1% ddm was used initially in preliminary experiments to help solubilize the enzyme from the cell lysate. a more complete detergent concentration profile was studied using 0.001% to 1% ddm with 83 µg/ml s2.5 Sf9 lysate containing human sCd1 and 10 nm [ 3 H]aze. the optimal detergent concentration for maximal ligand binding was between 0.01% and 0.1% (data not shown). above or below this range resulted in a loss of signal. subsequent experiments used 0.01% ddm.
Optimal enzyme and ligand concentration using human Flag-SCD1
a two-dimensional matrix experiment was performed varying the amount of affinity-purified human FlaG-sCd1 from 0 to 4.4 µg/ml and radioligand concentration from 0.003 to 233 nm to probe the relationship between enzyme and radioligand concentration relative to assay signal and window. a threedimensional plot of the resulting counts is shown in Figure 3A with total counts on the y-axis and radioligand versus enzyme concentration on the xand z-axis, respectively. the radiolabeled ligand [ 3 H]aze binds to human FlaG-sCd1 in a saturable manner for all enzyme concentrations tested. a dose-response curve for each enzyme concentration was plotted (Fig. 3b ) and the data fitted to a one-site model to give an estimate of the k d at each enzyme concentration. the k d was observed to decrease with decreasing protein. the optimal signal-to-background condition with a window of 18-fold was found to be 4.4 µg/ml enzyme with 78 nm radioligand. the lowest amount of purified human FlaG-sCd1 that could be used and still obtain a fivefold window was 0.07 µg/ml with 3 nm radioligand.
this experiment was repeated using unpurified FlaG-sCd1 in s2.5 Sf9 lysate from 0 to 0.6 mg/ml and radioligand concentration from 0.003 to 233 nm. a three-dimensional plot of the resulting counts is shown in Figure 4A with total counts on the y-axis and radioligand versus s2.5 Sf9 lysate concentration on the xand z-axis, respectively. at Sf9 lysate concentrations above 160 µg/ml, decreased specific binding to the endogenous sCd1 was observed. a window of 20-fold was observed using a lysate concentration of 40 µg/ml with 9 nm radioligand. similar to the data obtained with purified sCd1, the k d was observed to decrease with decreasing lysate concentration (Fig. 4b ). a minimum of 10 µg/ml Sf9 lysate containing recombinant FlaG-sCd1 with 1 nm radioligand could be used to obtain a fivefold window.
Rat liver microsomes
an excellent source of sCd1 protein can be obtained from liver microsomes of rats fed a high-carbohydrate diet. 26 the sPa assay using yttrium silicate beads was optimized for rat liver microsome concentration and radioligand probe concentration in a two-dimensional matrix experiment with a twofold serial dilution of microsomes starting at 290 µg/ml and a threefold serial dilution of radiolabeled probe starting at 233 nm. a three-dimensional plot of the resulting counts is shown in Figure 5A with total counts on the y-axis and radioligand versus rat liver microsome concentration on the xand z-axis, respectively. a 12-fold window was observed at the maximal amount of microsomes used (290 µg/ml) and 0.96 nm radioligand. Higher radioligand resulted in a larger background (nsB), which reduced the overall window. at rat liver microsome concentrations above 72 µg/ml, decreased specific binding to the endogenous sCd1 was observed. a minimum of 9 µg/ml rat liver microsomes with 0.96 nm radioligand could be used to obtain a fivefold window. Biphasic dose-response curves from this experiment are shown in Figure 5b with the high affinity binding half-saturation occurring around 1 nm irrespective of microsome concentration. a lower affinity binding appears to occur above 10 nm radioligand. a summary of binding parameters for the binding assay with different sCd1 sources is given in table 1.
Competition with SCD1 inhibitors
a titration of unlabeled aze and three other sCd1 inhibitors-mF-127, mF-183, and mF-152 27 -was conducted against purified human sCd1, s2.5 Sf9 lysate containing recombinant human sCd1, and rat liver microsomes. the dose-response curves for the inhibitors are shown in Figure 6 , and a summary of the iC 50 determined from a four-parameter fit of the curves is given in table 2 and compared against the potency in the enzyme activity assay.
HTS screen
using the 96-well yttrium sPa assay with s2.5 Sf9 lysate containing recombinant human FlaG-sCd1, the binding assay was miniaturized to a 1536 well, evaluating lowest protein and radioligand concentration for optimal window. the final conditions chosen to give a 10-fold window were as follows: 50 mm tris (pH 7.5) with 0.01% ddm, 28 µg/ml s2.5 Sf9 lysate of human Flag-sCd1, 13 nm radioligand, and 2.7 mg/ml yttrium oxide imaging beads. the sPa binding mixture was incubated for 15 min at room temperature and read on the Viewlux CCd imager and percentage inhibition determined.
to determine the well-to-well variance as well as plate effects, signal-to-background ratio and z′ factors were determined measuring total binding (132 wells) and nonspecific binding (no enzyme controls, 132 wells) across five 1536-well plates. the total binding was about 140 units, and the nonspecific binding decreased from 22 units to 6 units over the five plates as the plates in the Viewlux stacker adapted to the dark. all future experiments were conducted in subdued lab lighting to avoid this background shift. overall, the signal to background was about 14, and the calculated z′ factor was on average 0.8. Before initiation of the Hts campaign, 20 model compounds covering a range of potency from 1 to 5000 nm (based on the rat microsomal sCd1 activity assay) were titrated in the sPa binding Hts assay conditions using two incubation times of 10 min and 1.5 h. there was no difference in the iC 50 s found using a 10-min or 1.5-h incubation, and the subsequent Hts campaign was conducted using a 15-min incubation time before reading the plate. excellent correlation between the potency of the compounds determined by the rat liver microsomal sCd1 activity assay and the human sCd1 sPa binding assay was found with the binding assay, giving on average a 10-fold higher iC 50 than the enzyme assay. a sample collection of 1.6 million compounds at 11 µm was tested with the sPa assay using [ 3 H]aze and s2.5 Sf9 lysate containing human FlaG-sCd1. approximately 12 000 compounds were found to have >35% inhibition, giving a hit rate of 0.8%. Confirmation of the hits was done in triplicate at 11 µm, and 64% of the hits were reconfirmed. the frequency distribution of the hits is shown in Figure 7 . Within the confirmed hit list, ~200 compounds had rat liver microsomal sCd1 activity assay iC 50 data. a plot of percentage inhibition from the Hts sPa binding assay versus known iC 50 showed excellent correlation between the two assays, assuming a 10-fold shift between the binding assay and the enzyme assay (Fig. 8) .
the Hts hit list of 7700 compounds was filtered to avoid unwanted substructures and clustered into similar structures to give 830 compounds, which were tested at three concentrations (20, 4 , and 0.8 µm) in the rat liver microsomal sCd1 activity assay. in total, 154 compounds were identified with percentage inhibition >50% at 20 µm, with 49 compounds titrating with percentage inhibition >50% at 0.8 µm. the iC 50 s of these 49 compounds were determined by 10-point titration in the rat liver microsomal sCd1 activity assay. twenty compounds showed iC 50 s <100 nm, with four compounds giving iC 50 s less than 10 nm. all compounds were tested for delta 5 and delta 6 desaturase activity and found to be inactive against these two desaturases (data not shown). table 3 shows the structures of two structural classes of compounds that were identified as hits from this Hts campaign. optimization of these leads led to the discovery of mF-8 and mF-43 (see Powell et al. 28 dIScuSSIon scintillation proximity assays involve the capture of a target protein onto a bead embedded with scintillant followed by addition of radioactive ligand. When the ligand is brought into close proximity to the scintillant bead through binding to the target, light is emitted by the excited scintillant. the sPa technology has the advantage over filter-based binding assays of being homogeneous with no filtration or washing steps; the assays are robust and amenable to Hts. For sPa assays, the radioligand should bind to the target of interest with sufficient potency such that a low concentration of radioligand can be used to obtain adequate binding and avoid nonproximity and nonspecific binding effects, which can result in high backgrounds and low signal-to-noise ratios. For most sPa assays with enzymes as targets, this requires a compound that can bind with a k d <50 nm and be amenable to radiolabeling with either tritium or radioactive iodine. several inhibitors for human and rat sCd1 were identified 23 and tested for their nonspecific binding properties. Compound aze was found to have sufficient potency against both human and rat sCd1 with iC 50 s <10 nm, and the compound did not adhere significantly to plastic or glass.
to illustrate the potential use of the radiolabeled aze as a reversible ligand for development in a binding assay format, initial studies were conducted using gel filtration-based methods to separate ligand-bound sCd1 from unbound sCd1. the radiolabeled aze was able to reversibly bind to purified human sCd1.
in developing the sPa assay, the type of scintillant-embedded bead being PVt or ytt can be important, especially when screening large compound libraries. PVt sPa beads have the disadvantage that many compounds have been known to adhere to plastic, especially for large libraries. 29 ytt sPa beads can be more difficult to work with for dispensing the glass beads. as the sCd1 is FlaG-tagged, an antibody-linked sPa method was explored using both PVt and ytt antimouse scintillant beads with and without FlaG antibody. the protein bound to the glass bead regardless of the presence of the FlaG antibody. For PVt beads, the FlaG antibody was necessary to have substantial sCd1 bound to the bead. the sPa assay with ytt or PVt scintillant beads in the presence of anti-FlaG and [ 3 H] aze gave good signals, with ytt beads giving slightly lower nonspecific background compared to the plastic beads. the method using the ytt scintillant beads was chosen based on the lower nonspecific binding and lower cost associated with not using the FlaG antibody.
in the preparation of membrane-associated sCd1, detergent was added to solubilize the protein. Compared with detergents such as CHaPs, triton X-100, or tween-20, ddm was found to give the best solubilization without being detrimental to the enzyme activity (data not shown). Between 0.01% and 0.1% was necessary to give optimal sPa binding signal.
to optimize the amount of protein and ligand, the concentration of both was varied using several sources of sCd1, including affinity-purified human sCd1, s2.5 Sf9 lysate containing recombinant human sCd1, mock-infected s2.5 Sf9 lysate, and sugar-fed and fasted rat liver microsomes containing rat sCd1. regardless of sCd1 protein source, excellent signal-to-noise ratios of 15-to 20-fold were obtained using ligand concentrations at half of total maximal binding (i.e., near k d ). Control samples using mockinfected s2.5 Sf9 lysate or fasted rat liver microsomes with little to no sCd1 protein present did not show any significant specific binding of the radioligand to the beads compared with beads alone.
in the enzyme activity assay, three enzymes are required for the desaturase system: nadH-dependent cytochrome b5 reductase, cytochrome b5, and sCd. 30 rat liver microsomes contain all three enzymes. With purified FlaG-sCd1 or s2.5 Sf9 lysate containing recombinant FlaG-sCd1, supplementation with cytochrome b5 and cytochrome b5 reductase is required for desaturase activity. the binding of [ 3 H]aze to sCd1 was found to be independent of either cytochrome b5 or cytochrome b5 reductase, suggesting that these two redox enzymes do not affect the conformation of the aze binding site in sCd1. Xenon as a comparison, the structure of the first sCd1 inhibitor by Xenon Pharmaceuticals is included. 30 For human sCd1, a ligand dose-response curve at each enzyme concentration was generated and the apparent k d determined. the k d for affinity-purified and s2.5 lysate human FlaG-sCd1 was found to decrease dose-proportionally to the enzyme concentration, suggesting that the ligand is titrating the enzyme similarly to a reversible tight-binding inhibitor. the true k d is estimated to be <2 nm. an estimate of the concentration of sCd1 in the s2.5 lysate can be made based on the amount of ligand required to bind the entire enzyme. approximately 4% of the total protein in s2.5 lysate from recombinant human FlaG-sCd1 Sf9 cells is estimated to be sCd1. rat liver microsomes from sugar-fed rodents contain high levels of active sCd1 compared with livers from chow-fed or fasted animals. 25 sPa binding dose-response curves using this source of sCd1 showed biphasic behavior suggesting two binding modes for the radiolabeled ligand. With rat liver microsomes from fasted animals, no sCd1 activity or protein is detectable (data not shown). using fasted treated liver microsomes, no binding of the radioligand was observed in a sPa assay, suggesting that the biphasic dose-response curves observed with the sugar-fed rat liver microsomes may be related to the higher sCd1 concentration. it is not possible to rule out the involvement of other proteins that could be induced in the liver microsomes by the high-carbohydrate diet. Further studies to explain the behavior of the ligand binding to the rat sCd1 will be required using purified rat sCd1.
Having determined the optimum condition of ligand and protein concentration, competition binding assays were conducted using known sCd1 inhibitors against the sugar-fed rat liver microsomes, affinity-purified human sCd1, and s2.5 Sf9 lysates from recombinant human sCd1. the rank order of potency for the four test compounds was the same regardless of the source of sCd1. in general, the potency was fivefold less in the binding assay using s2.5 Sf9 lysate containing human sCd1 compared with the activity assays with either the rat liver microsomes or the s2.5 Sf9 lysate human sCd1. especially for very potent compounds, the binding assay with the lysate appeared to bottom out at 30 nm compared with 1.5 nm with the purified sCd1. this may be partially explained by the protein shift caused by the Sf9 lysate proteins.
For screening purposes, the protein shift caused by the Sf9 lysate was not seen as significant compared with the high cost of obtaining a substantial quantity of purified human sCd1. For that reason, the Hts assay was developed using the s2.5 Sf9 lysate containing recombinant human sCd1 as the protein source. the sPa 96-well assay was successfully miniaturized to a 1536-well format using the Viewlux system. such miniaturization was not possible with the enzyme assay. Furthermore, the sPa Hts assay had the advantage of avoiding false positives derived from compounds that might affect the other redox enzymes (b5 and b5 reductase) or protein-protein interactions that could occur in the enzyme activity assay. several small-molecule inhibitors of human sCd1 have been described, starting with the first known sCd1 inhibitor from Xenon Pharmaceuticals in 2005. 31 the structure of this sCd1 inhibitor, as shown in table 3, contains an aminopyrimidine ring. since that initial disclosure, numerous structurally related analogs have appeared incorporating the aminopyrimidine ring. 23,32-34 through a rational design approach, researchers [35] [36] [37] have modified the original aminopyrimidine or amino thiazole core with a urea group/amido heterocycle to afford derivatives exemplified by mF-152 (see table 2 ). CV therapeutics has also described a structurally distinct series of sCd1 inhibitors. 38, 39 For a more complete review of sCd1 inhibitors with their corresponding structures, see liu. 40, 41 to discover other novel structural inhibitors of human sCd1, an uHts campaign was conducted using the 1536-well sPa Hts assay. a sample collection of 1.6 million compounds was tested at 11 µm with an overall hit rate of 0.8%. the whole campaign was completed within a 2-week period. Both the z′ and percentage coefficient of variation (CV) for this screen were well within acceptable levels. to avoid testing all 7700 sPa binding actives in the low-throughput rat liver microsomal activity assay, structures were filtered and clustered to reduce the follow-up compound list to approximately 10% of the sPa active hits. evaluation of this subset of sPa hits in the rat liver microsomal activity assay confirmed that approximately 20% of the sPa binding hits have inhibitory activity against rat sCd1, with several compounds having iC 50 s less than 10 nm. two novel classes of compounds were identified from the current uHts campaign that varied from those previously described, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] both in terms of structure and biological properties. the benzimidazole class of compounds (example mF-1) demonstrated high human sCd1 selectivity over human sCd5 (>20 000-fold) and was selective against delta 5 and delta 6 desaturases (>20 000-fold). Further modification of this structural lead led to the development of a potent and selective human sCd1 inhibitor (mF-8). 27 Compound mF-8 was shown to have in vivo efficacy in a mouse liver Pd assay and represents the first described small-molecule inhibitor that is selective for the human sCd1 enzyme over the sCd5 isoform.
the other novel series that was identified from the Hts campaign was the triazole-based class of compounds (example mF-3), which showed high potency against both human sCd1 and sCd5 and selectivity against both delta 5 and delta 6 desaturases (>20 000-fold). Further optimization of this lead led to a potent, liver-targeting human sCd1 inhibitor (mF-43). although the triazole series had excellent in vitro potency against sCd1, this did not translate into in vivo potency. details on the optimization of the triazole class of sCd1 inhibitors will be described elsewhere (J.-P.leclerc, J.-P. Falgueyret, m. Girardin, J. Guay, s. Guiral, z. Huang, C.s. li, r. oballa, y.k. ramtohul, k. skorey, P. tawa, H. Wang, and l. zhang, unpublished data). the scintillation proximity assay for human sCd1 was found to be robust and amenable to uHts, allowing the rapid screening of more than 1.6 million compounds. several novel lead structures were identified using this sPa assay in an uHts campaign. the binding assay using the tight-binding radiolabeled ligand [ 3 H]aze can also provide a useful tool to measure sCd1 protein levels in various tissues. the sPa binding assay complements the enzyme activity assay in the search for inhibitors for sCd1 and potentially other sCd isoforms for the treatment of obesity and diabetes.
